OGN · Organon & Co. · Financials
$13.90
+0.01 (+0.07%)
At close · Nov 12
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$3.65B
Shares
262.62M
Volume · Nov 12
2.9M
Avg daily vol (3M)
2.63M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$6.22B
-2.9%
FY2025
Net Income
$187M
-78.4%
FY2025
Gross Margin
53.3%
-4.7pp
FY2025
Diluted EPS
$0.72
-78.4%
FY2025
Operating Cash Flow
$700M
-25.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| $6.2B | $6.1B | $6.22BG | $6.4BG | $6.26BG | $6.17BG | $6.3BG | $6.53B | $7.78B | |
| — | $2.86B | $2.9B | $2.69B | $2.52B | $2.29B | $2.38B | $2.12B | $2.27B | |
| — | $3.24B | $3.31B | $3.72B | $3.75B | $3.88B | $3.92Bd | $4.41Bd | $5.5Bd | |
| — | — | 53.3% | 58.02% | 59.84% | 62.84% | 62.21%d | 67.56%d | 70.76%d | |
| — | $357M | $366M | $469M | $528M | $471M | $443M | $210M | $220M | |
| — | $1.71B | $1.72B | $1.76B | $1.89B | $1.7B | $1.67B | $1.36B | $1.44B | |
| — | — | $205M | $145M | $116M | $116M | $103M | $86M | $284M | |
| — | $38M | $95M | $31M | $62M | $28M | $3M | $60M | $78M | |
| — | $446M | $504M | $520M | $527M | $422M | $258M | $0 | $0 | |
| — | $503M | $425M | $807M | $673M | $1.12B | $1.53B | $2.75B | $3.7B | |
| — | $290M | $238M | -$57M | -$350M | $205M | $178M | $496M | $390M | |
| — | $213M | $187M | $864M | $1.02B | $917M | $1.35B | $2.16B | $3.22B | |
| — | — | 3.01% | 13.49% | 16.33% | 14.85% | 21.43% | 33.07% | 41.38% | |
| — | $248M | $309M | $756M | $1.05B | $866M | $1.45B | $1.99B | $3.21B | |
| USD/shares | — | $0.80 | $0.72 | $3.36 | $4.01 | $3.61 | $5.33 | $8.52 | $12.69 |
| USD/shares | — | $0.77 | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 | $8.52 | $12.69 |
| shares | — | 262.62M | 259.5M | 257.05M | 255.24M | 254.08M | 253.54M | 253.52M | 253.52M |
| shares | — | — | 260.76M | 259.15M | 256.27M | 255.17M | 254.19M | 253.52M | 253.52M |
d Gross profit for periods the company did not report it, or tagged its operating income as gross profit, is Revenue − Cost of Revenue. Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $1.11B in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current debt and lease obligations | 2026-09-30 | USD 69,000,000 | 10-Q filed 2026-10-30 |
| Long-term debt, including current maturities | 2026-09-30 | USD 8,554,000,000 | 10-Q filed 2026-10-30 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.76×
Peer median 5.10×
EV/EBIT
—
P/E (TTM)
18.05×
Peer median 34.14×
Price/Sales (TTM)
0.60×
Peer median 3.60×
Price/Book
3.06×
Peer median 5.44×
Peer medians compare against the 7 similar-size Drug Manufacturers - General companies (of 15 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Europe and Canada | $1,618,000,000 | $1,763,000,000 | $1,673,000,000 | $1,631,000,000 | $1,741,000,000 | $1,726,000,000 | $1,893,000,000 |
| United States | $1,604,000,000 | $1,572,000,000 | $1,478,000,000 | $1,437,000,000 | $1,383,000,000 | $1,408,000,000 | $2,021,000,000 |
| Latin America Middle East Russia and Africa | $1,072,000,000 | $1,034,000,000 | $965,000,000 | $895,000,000 | $841,000,000 | $857,000,000 | $923,000,000 |
| Asia Pacific and Japan | $1,000,000,000 | $1,050,000,000 | $1,129,000,000 | $1,143,000,000 | $1,173,000,000 | $1,535,000,000 | $1,789,000,000 |
| China | $829,000,000 | $847,000,000 | $864,000,000 | $917,000,000 | $933,000,000 | $873,000,000 | $1,027,000,000 |
| Other Countries | $93,000,000 | $137,000,000 | $154,000,000 | $151,000,000 | $233,000,000 | $133,000,000 | $124,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Nexplanon Implanon NXT | $921,000,000 | $963,000,000 | $830,000,000 | $834,000,000 | $769,000,000 | $680,000,000 | $787,000,000 |
| Zetia | $342,000,000 | $317,000,000 | $322,000,000 | $370,000,000 | $378,000,000 | $482,000,000 | $590,000,000 |
| Other Sundry Established Brands | $338,000,000 | $328,000,000 | $319,000,000 | $326,000,000 | $357,000,000 | $379,000,000 | $238,000,000 |
| Atozet | $324,000,000 | $473,000,000 | $519,000,000 | $457,000,000 | $458,000,000 | $453,000,000 | $391,000,000 |
| Other Non Opiod Pain Bone and Dermatology | $301,000,000 | $295,000,000 | $275,000,000 | $273,000,000 | $286,000,000 | $278,000,000 | $214,000,000 |
| Arcoxia | $265,000,000 | $270,000,000 | $257,000,000 | $241,000,000 | $244,000,000 | $258,000,000 | $288,000,000 |
| Follistim AQ | $264,000,000 | $237,000,000 | $262,000,000 | $229,000,000 | $237,000,000 | $193,000,000 | $241,000,000 |
| Nasonex | $262,000,000 | $276,000,000 | $266,000,000 | $260,000,000 | $206,000,000 | $218,000,000 | $293,000,000 |
| Singulair | $252,000,000 | $359,000,000 | $404,000,000 | $411,000,000 | $413,000,000 | $462,000,000 | $698,000,000 |
| Renflexis | $251,000,000 | $274,000,000 | $278,000,000 | $226,000,000 | $186,000,000 | $135,000,000 | $96,000,000 |
| Hadlima | $228,000,000 | $142,000,000 | $44,000,000 | $19,000,000 | $13,000,000 | $0 | — |
| Cozaar Hyzaar | $219,000,000 | $243,000,000 | $281,000,000 | $323,000,000 | $357,000,000 | $386,000,000 | $442,000,000 |
| Emgality Ravvow | $174,000,000 | $107,000,000 | $0 | — | — | — | — |
| Other Womens Health | $174,000,000 | $158,000,000 | $147,000,000 | $138,000,000 | $206,000,000 | $270,000,000 | $173,000,000 |
| Dulera | $153,000,000 | $203,000,000 | $194,000,000 | $180,000,000 | $190,000,000 | $222,000,000 | $217,000,000 |
| Diprospan | $150,000,000 | $139,000,000 | $91,000,000 | $122,000,000 | $125,000,000 | $118,000,000 | $102,000,000 |
| Fosamax | $143,000,000 | $151,000,000 | $159,000,000 | $152,000,000 | $175,000,000 | $180,000,000 | $197,000,000 |
| Vtama | $128,000,000 | $12,000,000 | $0 | $0 | — | — | — |
| Marvelon Mercilon | $127,000,000 | $134,000,000 | $134,000,000 | $110,000,000 | $98,000,000 | $95,000,000 | — |
| Other Cardiovascular | $126,000,000 | $133,000,000 | $139,000,000 | $146,000,000 | $191,000,000 | $239,000,000 | $134,000,000 |
| Clarinex | $123,000,000 | $127,000,000 | $136,000,000 | $125,000,000 | $111,000,000 | $130,000,000 | $142,000,000 |
| Propecia | $118,000,000 | $111,000,000 | $125,000,000 | $125,000,000 | $136,000,000 | $129,000,000 | $131,000,000 |
| Ganirelix Acetate Injection | $101,000,000 | $109,000,000 | $110,000,000 | $123,000,000 | $111,000,000 | $81,000,000 | $112,000,000 |
| Vytorin | $100,000,000 | $108,000,000 | $129,000,000 | $130,000,000 | $164,000,000 | $182,000,000 | $285,000,000 |
| Ontruzant | $99,000,000 | $141,000,000 | $155,000,000 | $122,000,000 | $126,000,000 | $115,000,000 | $83,000,000 |
| Proscar | $97,000,000 | $95,000,000 | $97,000,000 | $101,000,000 | $117,000,000 | $176,000,000 | $203,000,000 |
| Nuva Ring | $91,000,000 | $115,000,000 | $176,000,000 | $219,000,000 | $191,000,000 | $236,000,000 | $879,000,000 |
| Other Sundry Products | $82,000,000 | $115,000,000 | $121,000,000 | $146,000,000 | $200,000,000 | $107,000,000 | $102,000,000 |
| Brenzys | $80,000,000 | $77,000,000 | $73,000,000 | $75,000,000 | $63,000,000 | $74,000,000 | $72,000,000 |
| Jada | $74,000,000 | $61,000,000 | $43,000,000 | $20,000,000 | $3,000,000 | — | — |
| Other Respiratory | $52,000,000 | $53,000,000 | $64,000,000 | $61,000,000 | $89,000,000 | $118,000,000 | $25,000,000 |
| Other Biosimilars | $33,000,000 | $28,000,000 | $43,000,000 | — | — | — | $0 |
| Rosuzet | $24,000,000 | $49,000,000 | $70,000,000 | $71,000,000 | $68,000,000 | $130,000,000 | $120,000,000 |
| Asmanex | — | — | — | — | — | — | $94,000,000 |
| Aybintio | — | — | — | $39,000,000 | $36,000,000 | $6,000,000 | — |
| Cerazette | — | — | — | — | — | — | $71,000,000 |
| Diprosone | — | — | — | — | — | — | $84,000,000 |
| Emgality Rayvow | — | — | — | $0 | — | — | — |
| Remeron | — | — | — | — | — | — | $82,000,000 |
| Sinemet | — | — | — | — | — | — | $79,000,000 |
| Zocor | — | — | — | — | — | — | $112,000,000 |
Key facts
CIK
1821825
CUSIP
68622V106
13F (30d)
460 filings
405 filers
Visit website
Investor relations